Logo

    thoracic oncology

    Explore " thoracic oncology" with insightful episodes like "Revolutionising Lung Cancer Healthcare with AI: Unlocking the Future", "Early Recovery After Surgery - Guidelines and Multidisciplinary Considerations", "Nature and nurture: lung cancer risk and implications for future screening", "Operability in Stage III NSCLC" and "NSCLC and KRAS Mutations" from podcasts like ""TOGA Podcast", "TOGA Podcast", "TOGA Podcast", "TOGA Podcast" and "TOGA Podcast"" and more!

    Episodes (13)

    Revolutionising Lung Cancer Healthcare with AI: Unlocking the Future

    Revolutionising Lung Cancer Healthcare with AI: Unlocking the Future
    Artificial intelligence (AI) is transforming medicine. Lung Cancer healthcare professionals are interested in the use of AI in radiology, particularly in early diagnosis leading to better patient outcomes. In this podcast we will explore how AI can aid in early detection, accurate interpretation of imaging scans and reduce diagnostic errors. This episode is joined by Associate Professor Michael Franco, a dual trained in medical oncology and palliative care and also the digital health director at Monash in Melbourne. He is featured with Professor Catherine Jones Cardiothoracic Radiologist I-Med Radiology and Clinical Director of Radiology at Redland Hospital, Brisbane and an expert on the Cancer Australia Expert Group for National Lung Cancer Screening Program. And accompanied by Dr Diane Pascoe a Consultant Radiologist and Deputy Director of Medical Imaging at Royal Melbourne Hospital.

    Early Recovery After Surgery - Guidelines and Multidisciplinary Considerations

    Early Recovery After Surgery - Guidelines and Multidisciplinary Considerations
    This TOGA Podcast discusses strategies for enhancing patients’ recovery from lung cancer resection in light of new and emerging data for new peri-operative therapies that improve survival. The conversation explores the guidelines available, the changing landscape for the patient with neoadjuvant and adjuvant management options, and the multidisciplinary considerations to optimise the care of patients. Dr Jazmin Eckhaus, a thoracic surgeon from The Austin, Melbourne, is joined by A/Prof Emily Stone, Head of Thoracic Medicine in the Dept of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney, A/Prof Melissa Moore, a medical oncologist from St Vincent’s in Melbourne and Chair of the TOGA Education Committee and Professor Catherine Granger, Head of Physiotherapy Research at The Royal Melbourne Hospital and an Associate Professor of Physiotherapy at The University of Melbourne in Australia. Professor Granger is a cardiorespiratory physiotherapist and clinician scientist with expertise in physical activity and exercise for cancer patients’ populations.

    Nature and nurture: lung cancer risk and implications for future screening

    Nature and nurture: lung cancer risk and implications for future screening
    This TOGA Podcast discusses the data surrounding air pollution and lung cancer. The discussion delves into Nature and nurture and lung cancer risk and implications for future screening. Associate Professor Tom John, Medical Oncologist from Peter MacCallum Cancer Centre, is joined by Professor Charles Swanton, The Group Leader at the Cancer Therapeutics Laboratory at the London Research Institute and Medical Oncologist from University College in London, Associate Professor Venessa Chin, a Medical Oncologist from St Vincent’s Private Hospital, Kinghorn Cancer Centre and Garvan Institute and Dr Tracy Leong, Respiratory Physician from Austin Health, Melbourne and President of the Victorian Branch, and Director of Lung Cancer, for TSANZ.

    Operability in Stage III NSCLC

    Operability in Stage III NSCLC
    In this TOGA Podcast, we discuss what defines operability in locally advanced stage III NSCLC. A/Professor Tim Clay, Medical Oncologist from St John of God Subiaco and Rockingham General is joined by Professor Lucy Morgan, Board Chair of the Lung Foundation of Australia and Respiratory Physician from Concord & Nepean Hospitals; A/Professor Phillip Antippa, Cardiothoracic surgeon and the Head of Thoracic Surgical Services at the Royal Melbourne Hospital and the VCCC and also Dr Qurrat van den Blink, Radiation Oncologist from GenesisCare based in Perth (Joondalup) and Albany.

    NSCLC and KRAS Mutations

    NSCLC and KRAS Mutations
    In this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O’Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response. Furthermore, the speakers give an update on current clinical research and approval status of KRAS inhibitors as well as the clinical need for the availability of KRAS inhibitors in Australia.

    Treatment Considerations in ALK-Positive NSCLC

    Treatment Considerations in ALK-Positive NSCLC
    In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient’s lifestyle.

    Brain metastases in NSCLC

    Brain metastases in NSCLC
    Recent studies in NSCLC patients with ALK or EGFR mutations and brain metastases, demonstrated greater benefit from the use of specific targeted therapies. In this Podcast, Associate Professor Paul Mitchell, Medical Oncologist from the Olivia Newton-John Cancer Centre, is joined by Dr Fiona Hegi-Johnson, Radiation Oncologist, Peter MacCallum Cancer Centre in Victoria, and Dr Dasantha Jayamanne, Radiation Oncologist, Genesis Care and Royal Northshore Hospital in NSW to discuss the management of brain metastases in NSCLC. They discuss the current data, the role of stereotactic radiation therapy (SRS, SABR, SBRT) and molecular drivers of ALK and EGFR in the management of these patients. Complex care is also discussed, as are intricacies and clinical considerations behind choosing and implementing care in NSCLC patients with brain metastases.

    NGS panels in lung cancer

    NGS panels in lung cancer
    In this Podcast, Dr Malinda Itchins, Medical Oncologist at Royal North Shore Hospital, Co-Chair of the Advanced Non-Small Cell Lung Cancer Group for TOGA and the Lung Cancer Chair of COSA, is joined by Professor Stephen Fox, Director of Pathology and Head of the Molecular Pathology Laboratory at the Peter MacCallum Cancer Centre in Melbourne Victoria and Professor Michael Millward, Medical Oncologist and Cancer Council Professor of Clinical Cancer Research School of Medicine, University of Western Australia to discuss NGS panels in lung cancer. They discuss the logistics and other considerations behind choosing and implementing NGS panels and the potential future application of this technology in clinical management of NSCLC. Keen to hear more beyond this podcast? Save the date 19 July 2023 for a f2f workshop in Melbourne discussing the various technologies for molecular testing, considerations for implementation and downstream applications. Registration will be part of TOGA ASM 2023 registrations expected to open by April 2023.

    The Management of Stage III NSCLC

    The Management of Stage III NSCLC

    Welcome to the Thoracic Oncology Group of Australasia Podcast series. Associate Professor Shankar Siva, Radiation Oncologist and current Cancer Council Victoria Colebatch Fellow who leads the SABR program at Peter MacCallum Cancer Centre discusses The Management of Stage III NSCLC in this podcast. Shankar is joined by Associate Professor Rachel Wong, Deputy Director of Oncology - Eastern Health, Adjunct Clinical Assoc Professor - Monash University and Clinical Research Fellow – WEHI and also Professor Drew Moghanaki, Chief of Thoracic Oncology, Department of Radiation Oncology at UCLA, Stanley Lezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research, Co-Director Greater Los Angeles Lung Precision Oncology Program and Co-Director Greater Los Angeles CSP NODES Program also joins us today. Our focus today is on what defines inoperable NSCLC, patient selection and how to manage the toxicities associated with treatment.

    Thank you to AstraZeneca for sponsoring this podcast.

    The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

    The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

    Welcome to the Thoracic Oncology Group of Australasia Podcast series. In this Podcast, we discuss early NSCLC management and treatment, particularly in light of how immunotherapy will impact surgical and respiratory medicine as the landscape evolves with new data. Dr Melissa Moore Medical Oncologist from St Vincent’s Melbourne and the TOGA Education Chair, is joined by Dr Katharine See, Director and Head of the Respiratory Medicine at the Northern Hospital, Melbourne and Mr Naveed Alam, Thoracic surgeon from St Vincent’s and Epworth, Melbourne to discuss and review the findings and implications for NSCLC patients.

     

    Thank you to Roche for collaborating on this podcast.

    Consider Every Trial as a TeleTrial

    Consider Every Trial as a TeleTrial

    Barriers and facilitators and a unique insight into the patient benefits are discussed between Alexandra, patient advocate, teletrials participant and lung cancer survivor, Sabe Sabesan, medical oncologist from the ICON Cancer Centre in Townsville and co-chair of the Australian Teletrial program and the initial teletrials pilot in 2017-2020, and Craig Underhill, medical oncologist from Border Medical Oncology and Haematology in Albury/Wodonga. Incentive funding and harmonising governance requirements for TeleTrials in Australia will help solve many of these issues and continue to transform the way trials are managed. The benefits for patients and their families are clear and positively impact the future of trials in Australia.

     

    Resources:          https://wiki.cancer.org.au/australia/COSA:Teleoncology

    https://www.digitalhealth.gov.au/healthcare-providers/initiatives-and-programs/telehealth

                                https://thoraciconcology.org.au/teletrials/

     

    Supported by Takeda

    Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.  

    The OJC Episode 33: Was Beethoven's death the result of medical malpractice?

    The OJC Episode 33: Was Beethoven's death the result of medical malpractice?

    The Oncology Journal Club - Delivering Oncology News Differently

    The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 33 in our series The Oncology Journal Club.

    Was Beethoven's death the result of medical malpractice? This week the OJC team tackle this crucial question plus the microbiome, trial design bias, five year outcomes for metastatic non-small-cell lung cancer and much more...

    Hans Prenen gets us started by talking us through the connection between the gut microbiome and immune checkpoint inhibitors and Eva Segelov has a mega paper this week…  She tackles our friend Bishal Gyawali’s paper addressing biases in study design that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale. Fascinating stuff!

    Then Craig Underhill gives us his thoughts on Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer.

    Today’s quick bites are as diverse as ever covering highlights from the AACR ASM, Fecal transplants for patients with cachexia, the TAPUR trial, Controversies in Thoracic Oncology, the costs of fear of cancer recurrence and much more.

    With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!

    Full bios and the list of all papers discussed are available on our website.

    For the latest oncology news visit
    www.oncologynews.com.au and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter.

    The Oncology Podcast - An Australian Oncology Perspective

    2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer

    2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer

    Remarkable advances in screening, diagnosing and treating lung cancer are discussed in this Podcast. Associate Professor Nick Pavlakis, Medical Oncologists from Royal North Shore Hospital Sydney and Dr Emily Stone, Respiratory Physician from St Vincent’s Hospital Sydney join TOGA for a conversation about public health measures to ensure the survival increase we are seeing for patients with lung cancer continues to accelerate into this decade.

    Sponsored with a Takeda Educational Grant.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io